0001213900-24-014996.txt : 20240216 0001213900-24-014996.hdr.sgml : 20240216 20240216180211 ACCESSION NUMBER: 0001213900-24-014996 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240214 FILED AS OF DATE: 20240216 DATE AS OF CHANGE: 20240216 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Reich Kristian CENTRAL INDEX KEY: 0001920553 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39630 FILM NUMBER: 24649902 MAIL ADDRESS: STREET 1: DORFSTRASSE 29 CITY: ZUG STATE: V8 ZIP: 6300 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MoonLake Immunotherapeutics CENTRAL INDEX KEY: 0001821586 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: DORFSTRASSE 29 CITY: ZUG STATE: V8 ZIP: 6300 BUSINESS PHONE: 41 41 510 8022 MAIL ADDRESS: STREET 1: DORFSTRASSE 29 CITY: ZUG STATE: V8 ZIP: 6300 FORMER COMPANY: FORMER CONFORMED NAME: Helix Acquisition Corp DATE OF NAME CHANGE: 20200818 4 1 ownership.xml X0508 4 2024-02-14 0 0001821586 MoonLake Immunotherapeutics MLTX 0001920553 Reich Kristian C/O MOONLAKE IMMUNOTHERAPEUTICS DORFSTRASSE 29 ZUG V8 6300 SWITZERLAND 0 1 0 0 Chief Scientific Officer 1 Class A ordinary shares, par value $0.0001 per share 2024-02-14 4 S 0 10000 62.42 D 3017483 I See footnote. Class A ordinary shares, par value $0.0001 per share 2024-02-14 4 S 0 10000 62.43 D 130071 D Class A ordinary shares, par value $0.0001 per share 2024-02-15 4 S 0 10000 60.17 D 3007483 I See footnote. Class A ordinary shares, par value $0.0001 per share 2024-02-15 4 S 0 10000 60.16 D 120071 D Class A ordinary shares, par value $0.0001 per share 2024-02-16 4 S 0 10000 60.15 D 2997483 I See footnote. Class A ordinary shares, par value $0.0001 per share 2024-02-16 4 S 0 10000 60.15 D 110071 D This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 16, 2023. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $61.82 to $63.01. Upon request by the staff of the U.S. Securities and Exchange Commission (the "Commission"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Beratungsgesellschaft mbH. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $61.82 to $63.01. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $58.10 to $63.95. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $58.18 to $63.95. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $59.34 to $61.17. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $59.34 to $61.17. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. /s/ Matthias Bodenstedt, Attorney-in-fact for Kristian Reich 2024-02-16